Tianjin Pharmaceutical Da Ren Tang ... (T14.SI)

$1.53

+0.04 (+2.68%)
Rating:
Recommendation:
-
Symbol T14.SI
Price $1.53
Beta 0.879
Volume Avg. 0.57M
Market Cap 3.748B
Shares () -
52 Week Range 0.925-1.53
1y Target Est -
DCF Unlevered T14.SI DCF ->
DCF Levered T14.SI LDCF ->
ROE -
ROA -
Operating Margin -
Debt / Equity -
P/E 10.20 Strong Buy
P/B -
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Ms. Niu Shengfang
Healthcare
Drug Manufacturers—Specialty & Generic
SES

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and healthcare products primarily in the People's Republic of China. It operates in Chinese Medicine and Western Medicine segments. The company is also involved in the manufacture and sale of Chinese and western pharmaceutical and biological products; wholesale and retail sale of medicines, biochemical pharmaceutical products, and daily use products; and operation of hospitals. In addition, it provides logistics, stocks, equipment installation, and medicine processing services; medicine inspection and testing services; and pharmaceutical consultancy services. The company sells its medicinal products under its own brand to the wholesalers; and purchases medicinal products under other brands from distributors and sells these to other wholesalers. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited and changed its name to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in May 2022. Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited was incorporated in 1992 and is based in Tianjin, the People's Republic of China.